Get the Stockscreener App
22.75
3.64%
0.80
After Hours:
22.75
Arrivent Biopharma Inc stock is traded at $22.75, with a volume of 239.75K.
It is up +3.64% in the last 24 hours and down -2.32% over the past month.
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.
See More
Previous Close:
$21.95
Open:
$22.34
24h Volume:
239.75K
Relative Volume:
0.48
Market Cap:
$1.01B
Revenue:
-
Net Income/Loss:
$-166.31M
P/E Ratio:
-5.1007
EPS:
-4.4602
Net Cash Flow:
$-160.59M
1W Performance:
-0.26%
1M Performance:
-2.32%
6M Performance:
+32.50%
1Y Performance:
+19.80%
1-Day Range:
$22.34
$22.98
1-Week Range:
$21.09
$23.20
52-Week Range:
$15.47
$27.22
Arrivent Biopharma Inc Stock (AVBP) Company Profile
Name
Arrivent Biopharma Inc
Sector
Industry
Phone
240-780-6356
Address
18 CAMPUS BLVD., NEWTOWN SQUARE
Compare AVBP vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVBP
Arrivent Biopharma Inc
|
22.75 | 970.23M | 0 | -166.31M | -160.59M | -4.4602 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Arrivent Biopharma Inc Stock (AVBP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-12-26 | Resumed | BTIG Research | Buy |
| Dec-10-25 | Initiated | BTIG Research | Buy |
| Nov-25-25 | Initiated | Truist | Buy |
| Jul-10-25 | Resumed | Goldman | Buy |
| Mar-20-25 | Initiated | B. Riley Securities | Buy |
| Mar-10-25 | Initiated | Guggenheim | Buy |
| Jul-22-24 | Initiated | Oppenheimer | Outperform |
| Apr-30-24 | Initiated | H.C. Wainwright | Buy |
| Feb-20-24 | Initiated | Citigroup | Buy |
| Feb-20-24 | Initiated | Goldman | Buy |
| Feb-20-24 | Initiated | Jefferies | Buy |
View All
Arrivent Biopharma Inc Stock (AVBP) Latest News
ArriVent to present preclinical cancer drug data at AACR 2026 - MSN
Burkina Faso Integrates National Languages into AI Development Strategy - TechAfrica News
Weekly Investment Analysts’ Ratings Changes for ArriVent BioPharma (AVBP) - Defense World
ArriVent to Present Preclinical Cancer Drug Data at AACR 2026 - MyChesCo
ArriVent BioPharma: Phase 3 Delay May Signal Stronger Outcomes For Firmonertinib (NASDAQ:AVBP) - Seeking Alpha
Discipline and Rules-Based Execution in AVBP Response - Stock Traders Daily
ArriVent BioPharma (NASDAQ:AVBP) Price Target Raised to $45.00 at B. Riley Financial - MarketBeat
B. Riley Securities Maintains Buy on ArriVent... - Benzinga
Weekly Earnings: Is ArriVent BioPharma Inc subject to activist investor interest2026 Price Swings & Fast Moving Market Watchlists - baoquankhu1.vn
Is ArriVent BioPharma (AVBP) Offering Value After Recent Share Price Pullback? - Sahm
Is ArriVent BioPharma, Inc. (AVBP) stock outpacing its medical peers this year? - MSN
ArriVent BioPharma (AVBP) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
ArriVent BioPharma Unveils Promising Preclinical Data on Firmonertinib and Dual-Target ADC ARR-002 at 2026 AACR Annual Meeting - Minichart
Truist Securities Initiates Coverage of ArriVent BioPharma (AVBP) with Buy Recommendation - MSN
Aarvik Therapeutics Showcases Novel ADC Molecules Based On MUTTA™ and AQUALINK™ Platforms at AACR 2026 - The National Law Review
ArriVent Highlights Next-Generation Oncology Data at AACR 2026 - TipRanks
ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting - The Manila Times
ArriVent to present preclinical data on firmonertinib and dual-target ADC ARR-002 at AACR 2026 - TradingView
ArriVent BioPharma (AVBP) to showcase firmonertinib and ARR-002 preclinical data at AACR 2026 - Stock Titan
Lung and ovarian cancer drug data from ArriVent to debut at 2026 AACR - Stock Titan
Stock Report: What drives Assurant Incs stock price2026 Sentiment & Verified Entry Point Detection - baoquankhu1.vn
ArriVent BioPharma, Inc. $AVBP Shares Sold by Hidden Lake Asset Management LP - MarketBeat
Anson Funds Management LP Makes New Investment in ArriVent BioPharma, Inc. $AVBP - MarketBeat
ArriVent BioPharma (AVBP) Stock Analysis Report | Financials & Insights - Benzinga Japan
Suvretta Capital Management LLC Buys 290,664 Shares of ArriVent BioPharma, Inc. $AVBP - MarketBeat
ArriVent BioPharma (NASDAQ:AVBP) Upgraded at BTIG Research - MarketBeat
Wall Street analysts see a 70.37% upside in ArriVent BioPharma, Inc. (AVBP): Can the stock really move this high? - MSN
Behavioral Patterns of AVBP and Institutional Flows - Stock Traders Daily
ArriVent BioPharma's (AVBP) Buy Rating Reaffirmed at BTIG Research - MarketBeat
ArriVent: Undervalued EGFR Franchise With Pivotal Firmonertinib Upside and Emerging ADC Optionality Driving Buy Rating and $42 Target - TipRanks
BTIG initiates ArriVent stock coverage with buy rating on oncology pipeline - Investing.com Canada
ArriVent Reports 2025 Results, Plans Phase 3 Data for Firmonertinib - MyChesCo
ArriVent BioPharma (NASDAQ:AVBP) Sees Strong Trading VolumeHere's What Happened - MarketBeat
Is ArriVent BioPharma, Inc. (AVBP) Shares Surpassing Other Medical Stocks in Performance This Year? - Bitget
Wall Street Analysts See a 70.37% Upside in ArriVent BioPharma, Inc. (AVBP): Can the Stock Really Move This High? - Yahoo Finance
Is ArriVent BioPharma, Inc. (AVBP) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
A Look At ArriVent BioPharma (AVBP) Valuation After Recent Share Price Swings - Sahm
Cantor Fitzgerald initiates coverage of ArriVent BioPharma (AVBP) with overweight recommendation - MSN
Whats the profit margin of ArriVent BioPharma IncWeekly Trend Summary & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Guggenheim Sticks to Their Buy Rating for ArriVent BioPharma, Inc. (AVBP) - The Globe and Mail
ArriVent BioPharma's (AVBP) Outperform Rating Reaffirmed at Oppenheimer - MarketBeat
ArriVent BioPharma (NASDAQ:AVBP) Price Target Raised to $33.00 - MarketBeat
Is ArriVent BioPharma (AVBP) Pricing Reflect Its DCF Value After Recent Share Gains - simplywall.st
ArriVent BioPharma Sees Unusually High Options Volume (NASDAQ:AVBP) - MarketBeat
Oppenheimer Adjusts Price Target on ArriVent BioPharma to $50 From $44, Maintains Outperform Rating - marketscreener.com
ArriVent BioPharma (NASDAQ:AVBP) Price Target Raised to $44.00 - MarketBeat
Jones Trading Initiates Coverage of ArriVent BioPharma (AVBP) with Buy Recommendation - MSN
ArriVent BioPharma Reports 2025 Financial Results and Advances Firmonertinib & ADC Pipeline with Key Phase 3 NSCLC Trials and Cash Runway Into 2027 - Minichart
EPS Watch: Whats next for ArriVent BioPharma Inc stock2025 Buyback Activity & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn
ArriVent BioPharma (NASDAQ:AVBP) Announces Earnings Results, Beats Expectations By $0.09 EPS - MarketBeat
ArriVent BioPharma Reports Full Year 2025 Financial Results - Bitget
Arrivent Biopharma Inc Stock (AVBP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):